Carbidopa Formulations with Antioxidants for Parkinson's Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease, primarily using levodopa, suffer from short half-life leading to pulsatile dopaminergic stimulation, resulting in motor fluctuations and dyskinesia, and are invasive and inconvenient. Additionally, levodopa requires large doses due to extracerebral metabolism, causing side effects like nausea.
Innovation Solution
Development of carbidopa or carbidopa ester formulations that include levodopa, along with two or more antioxidants such as ascorbic acid and cysteine derivatives, to enhance stability and reduce hydrazine levels, thereby providing a more continuous and physiologic dopaminergic stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If levodopa is administered alone, then dopaminergic stimulation is achieved, but motor fluctuations and dyskinesia occur due to short half-life and pulsatile stimulation
Solution Approach 1:
The patent combines levodopa with carbidopa (a dopa decarboxylase inhibitor) in a single formulation. Carbidopa inhibits peripheral metabolism of levodopa, extending its half-life and enabling more continuous dopaminergic stimulation while reducing pulsatile effects and motor complications.
Solution Approach 2:
The formulation includes antioxidants (ascorbic acid and cysteine derivatives) that preemptively protect levodopa and carbidopa from oxidation and degradation before administration. This preliminary protective action enhances stability and ensures consistent drug availability over time.
2Quantity of substance
If large doses of levodopa are administered to overcome extracerebral metabolism, then therapeutic effect is achieved, but side effects like nausea increase
Solution Approach 1:
Carbidopa acts as an intermediary substance that selectively inhibits peripheral dopa decarboxylase activity. This allows levodopa to reach the brain intact while minimizing peripheral conversion to dopamine, thereby reducing nausea and other side effects associated with high extracerebral dopamine levels.
3Object-generated harmful factors
If carbidopa is used to reduce levodopa dose, then side effects are reduced, but formulation stability decreases due to hydrazine generation
Solution Approach 1:
The patent converts the harmful oxidation of carbidopa (which generates hydrazine) into a beneficial process by adding antioxidants. The antioxidants selectively scavenge oxygen radicals that would otherwise oxidize carbidopa, allowing controlled metabolism while preventing harmful hydrazine accumulation and maintaining formulation stability.
Solution Approach 2:
The formulation modifies the redox environment by introducing antioxidants (ascorbic acid and cysteine derivatives), changing the oxidation-reduction parameters to favor carbidopa stability. This parameter change prevents hydrazine generation while maintaining carbidopa's pharmacological activity.
4Duration of action of moving object
If sustained-release formulations are used, then continuous delivery is attempted, but efficacy is not improved over standard tablets
Solution Approach 1:
The patent creates a composite formulation combining levodopa, carbidopa, and antioxidants in specific ratios. This composite approach leverages the synergistic effects of all components: carbidopa extends levodopa half-life, antioxidants protect both drugs from degradation, and the combination provides sustained therapeutic effect without relying on complex sustained-release mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations achieve improved stability and reduced hydrazine levels, leading to more effective and continuous dopaminergic stimulation with reduced motor complications and side effects, thus addressing the limitations of current levodopa treatments.
Implementation Method 1
The loss of the hydrazine functional group represents the major metabolic pathway for carbidopa... hydrazine (N2H4), or its salts, are used in the production of pharmaceutical products... Hydrazine has also been shown to cause DNA damage, gene mutations, and chromosome aberrations
Data Source
AI summary
Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.